Modena B D, Kurian S M, Gaber L W, Waalen J, Su A I, Gelbart T, Mondala T S, Head S R, Papp S, Heilman R, Friedewald J J, Flechner S M, Marsh C L, Sung R S, Shidban H, Chan L, Abecassis M M, Salomon D R
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA.
DNA Microarray and Next Generation Sequencing Core, The Scripps Research Institute, La Jolla, CA.
Am J Transplant. 2016 Jul;16(7):1982-98. doi: 10.1111/ajt.13728. Epub 2016 Mar 15.
Interstitial fibrosis and tubular atrophy (IFTA) is found in approximately 25% of 1-year biopsies posttransplant. It is known that IFTA correlates with decreased graft survival when histological evidence of inflammation is present. Identifying the mechanistic etiology of IFTA is important to understanding why long-term graft survival has not changed as expected despite improved immunosuppression and dramatically reduced rates of clinical acute rejection (AR) (Services UDoHaH. http://www.ustransplant.org/annual_reports/current/509a_ki.htm). Gene expression profiles of 234 graft biopsy samples were obtained with matching clinical and outcome data. Eighty-one IFTA biopsies were divided into subphenotypes by degree of histological inflammation: IFTA with AR, IFTA with inflammation, and IFTA without inflammation. Samples with AR (n = 54) and normally functioning transplants (TX; n = 99) were used in comparisons. A novel analysis using gene coexpression networks revealed that all IFTA phenotypes were strongly enriched for dysregulated gene pathways and these were shared with the biopsy profiles of AR, including IFTA samples without histological evidence of inflammation. Thus, by molecular profiling we demonstrate that most IFTA samples have ongoing immune-mediated injury or chronic rejection that is more sensitively detected by gene expression profiling. These molecular biopsy profiles correlated with future graft loss in IFTA samples without inflammation.
移植后1年的活检中,约25%发现存在间质纤维化和肾小管萎缩(IFTA)。已知当存在炎症组织学证据时,IFTA与移植肾存活率降低相关。明确IFTA的发病机制对于理解为何尽管免疫抑制有所改善且临床急性排斥反应(AR)发生率大幅降低,但长期移植肾存活率仍未如预期提高十分重要(美国卫生与公众服务部。http://www.ustransplant.org/annual_reports/current/509a_ki.htm)。获取了234份移植肾活检样本的基因表达谱,并匹配了临床和预后数据。81份IFTA活检样本根据组织学炎症程度分为亚表型:伴有AR的IFTA、伴有炎症的IFTA和无炎症的IFTA。将伴有AR的样本(n = 54)和功能正常的移植肾(TX;n = 99)用于比较。一项使用基因共表达网络的新分析显示,所有IFTA表型均强烈富集了失调的基因通路,且这些通路与AR的活检图谱相同,包括无炎症组织学证据的IFTA样本。因此,通过分子谱分析,我们证明大多数IFTA样本存在持续的免疫介导损伤或慢性排斥反应,基因表达谱能更灵敏地检测到这些情况。这些分子活检图谱与无炎症的IFTA样本未来的移植肾丢失相关。